When authors applied a combination treatment of cabozantinib and an MDM2 inhibitor, AMG232, on lung cancer, the synergistic therapy was shown to be more efficacious in suppressing lung cancer growth than monotherapy in vitro and in vivo, demonstrating that MDM2 amplification could be a potential mechanism of cabozantinib resistance in the clinic. The gene discussed is MDM2; the disease is lung cancer.